Exai Bio Secures $67.5 Million Series A Financing to Advance Next-Generation, RNA-Based Liquid Biopsy Platform for Early Cancer Detection Funding | Exai Bio .Labcorp Strengthens Oncology Leadership Position With the Addition of Personal Genome Diagnostics, a Provider of Comprehensive Liquid Biopsy and Tissue-Based Genomic Products and Services M&A | Labcorp, PGDx .
FORESIGHT DIAGNOSTICS TRIAL
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population Clinical Trial Launch | Grail.Foresight Diagnostics' PhasED-Seq ctDNA assay detects response to acalabrutinib as early as seven days in patients with aggressive B-cell lymphomas Clinical Trial Results | Foresight Diagnostics .Twist Bioscience Launches Circulating Tumor DNA Reference Controls for Development of Liquid Biopsy Assays Product Launch | Twist Bioscience.Flagship Pioneering Launches Harbinger Health to Detect Early Cancer with a Simple, Bio-AI Based Blood Test Company Launch | Flagship Pioneering .Freenome, Siemens join forces to develop blood test for breast cancer Partnership | Freenome .Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity Product Launch | Personalis .Epic Sciences unveils DefineMBC™, a novel blood-based test designed to improve care for metastatic breast cancer patients Product Launch | Epic Sciences .HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available Commercial Launch | HelioLiver. Quest Diagnostics Now Offers Biocept's Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer Diagnostics Commercial Partnership | Quest Diagnostics .GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test Medicare Coverage | GRAIL . End-of-the-year 2021 poised the Liquid Biopsy industry to have an explosive new year in 2022 with multiple medicare coverage designations, product launches, clinical trial progression, and promising funding rounds.
0 kommentar(er)
